Načítá se...
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigila...
Uloženo v:
| Vydáno v: | Clin Transl Radiat Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369349/ https://ncbi.nlm.nih.gov/pubmed/32715108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2020.06.013 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|